US approves first new Alzheimer’s drug in 20 years

In March 2019, the advanced international trials of aducanumab, involving around 3,000 patients, were halted when analysis showed that the drug, given as a monthly infusion, was not better at slowing the deterioration of the problems. of memory and reflection than a dummy drug.

Add a Comment